ArticleAnnals of medicine2026
Delayed diagnosis and genetic testing in spinal muscular atrophy: a case series.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Congenital Clubfoot as an Early Manifestation of Duchenne Muscular Dystrophy?Muscles (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpinal muscular atrophy (SMA) is a recessively inherited autosomal neuromuscular disorder that is associated with deletions or disease-causing variants in the survival motor neuron 1 ( CASE PRESENTATION: Patient 1 was a 21-year-old man who had experienced limb weakness and muscle atrophy for 20 years. At the age of 6, he underwent genetic testing and was diagnosed with SMA type II. Patient 2 was a 26-year-old man who had been complaining of progressive limb weakness for 11 years and muscle atrophy for 5 years. When he was 20 years old, he experienced muscle atrophy of both legs and was diagnosed with SMA type III after genetic testing. Patient 3 was a 40-year-old man who presented with slowly progressive lower limb weakness since the age of 15. He was misdiagnosed with Duchenne muscular dystrophy in age 20. He was referred to our clinic at the age 40 and was ultimately confirmed to have SMA after genetic testing. Patients 4 and 5 were sisters, who complained of lower limb weakness and were recently diagnosed with SMA.
conclusionsThis case series highlights the current status and possible reasons for delayed diagnosis and delayed initiation of treatment for SMA, including limited awareness of SMA, low accessibility of genetic testing, and uneven distribution of medical resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.